CLINICAL_TRIALS
trial_result
· 2016-11-02
Clinical Trial Update: A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
Summary
A Phase 1 study of the investigational agent DFRF4539A in patients with relapsed or refractory multiple myeloma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED